Liver-spleen axis: Deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications

doi:10.3748/wjg.119467

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 34

This Article

(3)

(4)

(0)

(18)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Sep 14, 2026; 32(34): 119467
Published online Sep 14, 2026. doi: 10.3748/wjg.119467

Full Size Figure Download Figure

Figure 9 Validated metrics for non-alcoholic fatty liver disease/chronic liver disease. Utilizing this suite of metrics enables physicians to longitudinally track disease progression, spanning the spectrum from initial hepatic steatosis to end-stage portal hypertension[193,194]. CAP: Controlled attenuation parameter; F: Fibrosis; LSM: Liver stiffness measurement; S: Steatosis; SSM: Spleen stiffness measurement.

Citation: Tarantino G, Citro V. Liver-spleen axis: Deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications. World J Gastroenterol 2026; 32(34): 119467
URL: https://www.wjgnet.com/1007-9327/full/v32/i34/119467.htm
DOI: https://dx.doi.org/10.3748/wjg.119467

Tarantino G, Citro V. Liver-spleen axis: Deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications. World J Gastroenterol 2026; 32(34): 119467 [DOI: 10.3748/wjg.119467]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.